<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309773</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180668</org_study_id>
    <nct_id>NCT04309773</nct_id>
  </id_info>
  <brief_title>Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy</brief_title>
  <acronym>BEZASCLER</acronym>
  <official_title>Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the effect of bezafibrate treatment compared to
      placebo on efficacy and safety in patients with primary sclerosing cholangitis (PSC) and
      persistent cholestasis despite ursodeoxycholic acid therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled, evaluation of the efficacy
      and safety of Bezafibrate in subjects with PSC and persistent cholestasis despite
      ursodeoxycholic acid therapy (UADC).

      Design:

        -  A multicentre, double-blind placebo controlled, randomised clinical trial

        -  35 centers participants to the recruitment (French Network of Reference and Competence
           Centers for Rare Diseases: &quot;inflammatory biliary diseases and autoimmune hepatitis&quot;
           (MIVBH), including Saint-Antoine hospital, Paris as reference coordinator center)

      Sample size :

      104 patients, 52 in each group

      Treatments groups:

        1. UADC therapy (15-20 mg/kg/d) + Bezafibrate (400mg/d)

        2. UDCA therapy (15-20 mg/kg/d) + placebo of bezafibrate (400mg/d)

      Treatments duration :

      24 months

      Assessement:

      Study visits at Inclusion, (M0) Randomisation and then every 3 months until M24

      This is a phase III randomized, double blinded, multicenter, study.

      No interim analysis is planned. Analysis will be performed at the end of the study after data
      review and freezing of data base according to intent to treat principle.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of 24-month treatment with bezafibrate (400 mg/day) versus placebo in addition to standard UDCA therapy in Primary Sclerosing Cholangitis (PSC).</measure>
    <time_frame>At 24 months</time_frame>
    <description>Proportion of patients with serum Alkaline Phosphatase &lt; 1.5 ULN and a reduction of at least 15% from baseline at M24 and normal serum bilirubin and no increase of liver stiffness at M24 compared to baseline:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clinical or biological adverse events</measure>
    <time_frame>At 24 months</time_frame>
    <description>Safety endpoint: Percentage of patients with clinical (including increased IBD activity) or biological adverse events (elevated creatinine (&gt; 150 μmol/L) or ALT (&gt; 5ULN) or AST (&gt; 5ULN) or CPK (&gt; 5ULN) during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of PSC patients</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <description>French version of the quality of life QMCF questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for pruritus</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <description>Absolute changes in the score for pruritus (measured by VAS and 5D pruritus scale) at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <description>Absolute changes in the score for fatigue (measured by adapted PBC-40 questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of liver biochemical parameters between the two groups of patient</measure>
    <time_frame>between month 0 and month 24</time_frame>
    <description>The course during the study will be studied using linear regression mixed model.
A random effect for each patient will be considered and treatment group will be considered as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinical events and transplant-free survival</measure>
    <time_frame>At 24 months</time_frame>
    <description>Survival rate without liver transplantation or hepatic events (ascites, variceal bleeding, encephalopathy, acute cholangitis, cholangiocarcinoma, hepatocellular carcinoma or serum total bilirubin &gt; 100 μmol/L for at least 3 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Bezafibrate in addition to standard UDCA therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (&quot;experimental&quot; arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of Bezafibrate in addition to standard UDCA therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy</intervention_name>
    <description>Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose</description>
    <arm_group_label>Bezafibrate in addition to standard UDCA therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Bezafibrate in addition to standard UDCA therapy</intervention_name>
    <description>Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose</description>
    <arm_group_label>Placebo of Bezafibrate in addition to standard UDCA therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥ 18 and ≤ 75 years

          -  Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance
             cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct
             changes consistent with PSC

          -  Colonoscopy within the last 5 years (or within 3 months if IBD is associated to PSC)
             with no cancer nor all-grade dysplasia

          -  ALP ≥ 1.5 ULN at baseline

          -  Treatment with UDCA (15-20 mg/kg/d) for ≥ 6 months before inclusion.

          -  Using contraceptive in childbearing women

          -  Affiliation to a social security system (AME excepted)

          -  Signed informed consent

        Exclusion Criteria:

          -  Child-Pugh score B or C

          -  Ascites or digestive hemorrhage (or history of)

          -  Total bilirubin in the last 3 months &gt; 50 μmole/L (3 mg/dl)

          -  Gilbert syndrome defined as unconjugated bilirubinemia &gt; 12 μmol/L

          -  Albumin in the last 3 months &lt; 35 g/L

          -  Prothrombin index in the last 3 months &lt; 70%

          -  Platelets count in the last 3 months &lt; 100000/mm3

          -  ALT or AST &gt; 5 ULN in the last 3 months

          -  Prior liver transplantation

          -  Treatment with a fibrate within the last 3 months inclusion or with a statin at
             inclusion

          -  Current active IBD defined as either current use of systemic corticosteroid therapy &gt;
             10 mg/day or budesonide &gt; 3 mg /day or immunosuppressive drugs (cyclosporine,
             tacrolimus, mycophenolate mofetil, mTor inhibitors) or biologics (vedolizumab,
             ustekinumab) or a partial Mayo score &gt; 2 in patients with ulcerative colitis (UC) or a
             Crohn's Disease Activity Index (CDAI) &gt; 150 in patients with Crohn's disease (CD)

          -  Dose change of treatment for associated IBD ≤3 months prior to inclusion

          -  Current or history of colonic cancer or all-grade dysplasia described at the last
             colonoscopy

          -  Any other cause of liver damage ((positive test for HBV, HCV, or HIV, excessive
             alcohol consumption, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency,
             celiac disease, autoimmune hepatitis defined by the presence of at least 2 of the 3
             following criteria; 1) AST or ALT &gt; 5 ULN, 2) Positive anti smooth muscle auto
             antibodies or serum IgG &gt; 1.5 ULN, 3) interface hepatitis on liver biopsy)

          -  Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis
             (elevated serum IgG4 &gt; 4 ULN)

          -  History of acute cholangitis in the last 3 months prior to inclusion or current acute
             cholangitis

          -  Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned
             within 3 months post randomization date

          -  History of or established or suspected hepatobiliary carcinoma.

          -  Any severe comorbidity that may reduce life expectancy

          -  History of malignancy diagnosed or treated within 2 years (recent localized treatment
             of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in
             situ is allowed if appropriately treated prior to Screening)

          -  Known hypersensitivity to bezafibrate, any of the components of Befizal© or other
             fibrates

          -  Known photosensitivity or photoallergy reactions to fibrate

          -  Patient with congenital galactosemia, glucose malabsorption, or lactase deficiency
             because of presence of lactose in 400 mg SR tablets of bezafibrate and in placebo
             tablets

          -  Pregnancy (or desire for)

          -  Renal insufficiency (clearance &lt; 60 ml/min or serum creatinine level &gt; 130 μmole/L)

          -  Breastfeeding

          -  Participation in any other interventional study or in the exclusion period any other
             interventional study

        Randomization exclusion criteria:

          -  Positive test for HBV (positive HBs Ag), HCV (positive HCV RNA), or HIV (positive
             serology)

          -  Pregnancy (or desire for in the 2 next years)

          -  Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis
             (elevated serum IgG4 &gt; 4 ULN)

          -  Autoimmune hepatitis defined by the presence of at least 2 of the 3 following
             criteria; AST or ALT &gt; 5 ULN, Positive anti smooth muscle auto antibodies or serum IgG
             &gt; 1.5 ULN, interface hepatitis on liver biopsy

          -  Current acute cholangitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHAZOUILLERES, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier CHAZOUILLERES, professor</last_name>
    <phone>+ 33149282380</phone>
    <email>olivier.chazouilleres@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe CORPECHOT, docteur</last_name>
    <phone>00 33 1 49 28 28 36</phone>
    <email>christophe.corpechot@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatology department - Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CHAZOUILLERES, Pr</last_name>
      <phone>+ 33 (0) 1 49 28 23 80</phone>
      <email>olivier.chazouilleres@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christophe Corpechot, Doctor</last_name>
      <phone>+ 33 (0) 1 49 28 28 36</phone>
      <email>christophe.corpechot@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary sclerosing cholangitis</keyword>
  <keyword>Persistent cholestasis</keyword>
  <keyword>Bezafibrates</keyword>
  <keyword>Fibrates</keyword>
  <keyword>UDCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

